Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Opens New Shanghai Facilities

Published: Thursday, March 29, 2012
Last Updated: Thursday, March 29, 2012
Bookmark and Share
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.

Novasep has announced the opening of a new 2,000 m2 facility in Shanghai Pudong district, China. The site will boost Novasep's process development and engineering capabilities to cater for ever-increasing Chinese and East Asian demand.

These facilities will also add to Novasep’s existing 12 global synthesis and process sites in France, US, Germany, Belgium and The Bahamas.

Novasep launched its previous facilities in Shanghai in 2006, and quickly outgrew the site whilst the company doubled its staff to almost 50 employees between 2010 and 2012.

The new 2,000 m2 expanded facilities includes 800 m2 dedicated to innovation and process development through new laboratory, piloting and FAT testing areas.

The ongoing growth of life sciences industries in China and Asia stretches local demand for domestic production and innovation capabilities.

Novasep has seen continued growth in demand in East Asia for its design and supply of purification technologies and integrated processes in batch and continuous membrane filtration, ion exchange and chromatography.

Novasep is also facing increasingly challenging purification requests, driven by the need for life science industries to reach maximum throughput with low capital and production costs and minimum environmental impact.

The increased innovation capabilities at the Shanghai site will allow Novasep to meet this demand, and advance on the 50 purification processes already developed by Novasep in Shanghai.

By increasing engineering capabilities, Novasep will expand output for its turnkey purification process solutions for its key markets:
• Industrial biotech: fructose, starch sweeteners, organic acids, amino acids, bulk antibiotics, nucleotides, polyols, white biotech applications, functional ingredients including whey products, oligosaccharides and omega 3,
• Biopharmaceuticals including recombinant proteins, peptides and biosimilars including monoclonal antibodies and insulin,
• Pharmaceuticals: especially optical isomers and certain anti-cancer APIs.

"Novasep, as the leader in the supply of purification processes for industrial biotech and biopharmaceutical applications in China, has ensured that its supply capabilities can satisfy ever increasing demands in China and East Asia," said Antoine Baule, president of Novasep Process, the biomolecule division of Novasep.

"With food and feed industry ingredient volumes rising above 100,000 tons per year in some Chinese productions, this requires more cost effective and environmentally friendly processes, and strong engineering capabilities,” said Jean de Lataillade, general manager of Novasep Asia.

Lataillade continued, “The Shanghai site will further enable Novasep to compete globally in both low volume pharma markets, as well as large volume industrial biotech markets.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Real-Time Imaging of Embryo Development Could Pave the Way
Researchers at IMCB have developed advanced microscopy technologies to monitor embryo development for more effective human reproduction therapies.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!